Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Dec 21, 2013; 19(47): 8861-8866
Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.8861
Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.8861
Anti-viral therapy to reduce recurrence and improve survival in hepatitis B virus-related hepatocellular carcinoma
Toru Ishikawa, Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, Niigata 950-1104, Japan
Author contributions: Ishikawa T collected the materials and wrote the manuscript.
Correspondence to: Toru Ishikawa, MD, PhD, Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, 280-7 Teraji, Niigata 950-1104, Japan. toruishi@ngt.saiseikai.or.jp
Telephone: +81-25-2336161 Fax: +81-25-2338880
Received: August 29, 2013
Revised: October 29, 2013
Accepted: November 28, 2013
Published online: December 21, 2013
Processing time: 143 Days and 22.5 Hours
Revised: October 29, 2013
Accepted: November 28, 2013
Published online: December 21, 2013
Processing time: 143 Days and 22.5 Hours
Core Tip
Core tip: Recent advances in treatment modalities have improved the survival rate of patients with hepatocellular carcinoma (HCC). However, hepatitis B virus (HBV)-related HCC has a much higher recurrence rate. In this article, we describe strategies for reducing recurrent HCC using anti-viral therapy for HBV infection.